Literature DB >> 9712755

A peptide domain on gingipain R which confers immunity against Porphyromonas gingivalis infection in mice.

C A Genco1, B M Odusanya, J Potempa, J Mikolajczyk-Pawlinska, J Travis.   

Abstract

The cysteine proteinases referred to as gingipains R (gingipain R1 and gingipain R2) and gingipain K produced by Porphyromonas gingivalis are virulence factors of this periodontal pathogen which likely act by interrupting host defense mechanisms and by participating in the penetration and destruction of host connective tissue. To examine the effect of immunization with gingipains R on the ability of P. gingivalis to colonize and invade in the mouse chamber model, BALB/c mice were immunized intraperitoneally with the 95-kDa gingipain R1, the 50-kDa gingipain R2, or multiple antigenic peptide (MAP)-conjugated gingipain R-derived peptides and then challenged with P. gingivalis. Immunization of mice with the 95-kDa gingipain R1, the 50-kDa gingipain R2, or a peptide derived from the N-terminal sequence of the catalytic domain of gingipains R (peptide A) followed by challenge with P. gingivalis A7436 resulted in protection from P. gingivalis invasion. In contrast, immunization with peptides corresponding to either a sequence encompassing the catalytic cysteine residue of gingipains R (peptide B) or an identical sequence within the catalytic domains of gingipain R1 and gingipain K (peptide C), followed by challenge with P. gingivalis, did not protect animals, nor did immunization with a peptide corresponding to sequences within the adhesion/hemagglutinin domain of gingipain R1 (peptide D) which have been shown to be directly involved in the hemagglutinin activity of gingipain R1. However, the immunoglobulin G (IgG) titer obtained following immunization with peptide D was comparable to that obtained following immunization with the N-terminal peptide (peptide A). Competitive enzyme-linked immunosorbent assays, using either the 95-kDa gingipain R1 or gingipain K as the competing soluble antigen, indicated that 42 and 53% of the antibodies induced by immunization with heat-killed bacteria recognize gingipain R1 and gingipain K, respectively; however, even at very high concentrations, the 50-kDa gingipain R2 did not hinder IgG binding to P. gingivalis. These results indicate that antibodies directed to the amino-terminal region of the catalytic domain of gingipains R are capable of inducing a protective immune response against P. gingivalis infection in the mouse chamber model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712755      PMCID: PMC108493          DOI: 10.1128/IAI.66.9.4108-4114.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Identification of Porphyromonas gingivalis prefimbrilin possessing a long leader peptide: possible involvement of trypsin-like protease in fimbrilin maturation.

Authors:  T Onoe; C I Hoover; K Nakayama; T Ideka; H Nakamura; F Yoshimura
Journal:  Microb Pathog       Date:  1995-11       Impact factor: 3.738

2.  Human serum antibody responses to oral microorganisms. IV. Correlation with homologous infection.

Authors:  J L Ebersole; M A Taubman; D J Smith; D E Frey; A D Haffajee; S S Socransky
Journal:  Oral Microbiol Immunol       Date:  1987-06

3.  The hemagglutinin gene A (hagA) of Porphyromonas gingivalis 381 contains four large, contiguous, direct repeats.

Authors:  N Han; J Whitlock; A Progulske-Fox
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 4.  Porphyromonas gingivalis: a proteinase/gene accounting audit.

Authors:  J Potempa; N Pavloff; J Travis
Journal:  Trends Microbiol       Date:  1995-11       Impact factor: 17.079

5.  Cysteine protease of Porphyromonas gingivalis 381 enhances binding of fimbriae to cultured human fibroblasts and matrix proteins.

Authors:  M Kontani; H Ono; H Shibata; Y Okamura; T Tanaka; T Fujiwara; S Kimura; S Hamada
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Serological identification of oral Bacteroides spp. by enzyme-linked immunosorbent assay.

Authors:  J L Ebersole; D E Frey; M A Taubman; D J Smith; S S Socransky; A C Tanner
Journal:  J Clin Microbiol       Date:  1984-05       Impact factor: 5.948

7.  Cell envelope and cell wall immunization of Macaca fascicularis: effect on the progression of ligature-induced periodontitis.

Authors:  S C Holt; M Brunsvold; A Jones; R Wood; J L Ebersole
Journal:  Oral Microbiol Immunol       Date:  1995-12

8.  Involvement of arginine-specific cysteine proteinase (Arg-gingipain) in fimbriation of Porphyromonas gingivalis.

Authors:  K Nakayama; F Yoshimura; T Kadowaki; K Yamamoto
Journal:  J Bacteriol       Date:  1996-05       Impact factor: 3.490

9.  Characterization of the binding activities of proteinase-adhesin complexes from Porphyromonas gingivalis.

Authors:  R N Pike; J Potempa; W McGraw; T H Coetzer; J Travis
Journal:  J Bacteriol       Date:  1996-05       Impact factor: 3.490

10.  Analysis of the prtP gene encoding porphypain, a cysteine proteinase of Porphyromonas gingivalis.

Authors:  G A Barkocy-Gallagher; N Han; J M Patti; J Whitlock; A Progulske-Fox; M S Lantz
Journal:  J Bacteriol       Date:  1996-05       Impact factor: 3.490

View more
  23 in total

1.  Role of gingipains in growth of Porphyromonas gingivalis in the presence of human serum albumin.

Authors:  D Grenier; S Imbeault; P Plamondon; G Grenier; K Nakayama; D Mayrand
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model.

Authors:  N M O'Brien-Simpson; R A Paolini; E C Reynolds
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology.

Authors:  Maximilian F Konig; Alizay S Paracha; Malini Moni; Clifton O Bingham; Felipe Andrade
Journal:  Ann Rheum Dis       Date:  2014-05-26       Impact factor: 19.103

4.  Porphyrin-mediated binding to hemoglobin by the HA2 domain of cysteine proteinases (gingipains) and hemagglutinins from the periodontal pathogen Porphyromonas gingivalis.

Authors:  A A DeCarlo; M Paramaesvaran; P L Yun; C Collyer; N Hunter
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

5.  Arg-gingipain a DNA vaccine induces protective immunity against infection by Porphyromonas gingivalis in a murine model.

Authors:  H Yonezawa; K Ishihara; K Okuda
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

6.  Specific antibodies to Porphyromonas gingivalis Lys-gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection.

Authors:  M Kuboniwa; A Amano; S Shizukuishi; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Attenuation of the virulence of Porphyromonas gingivalis by using a specific synthetic Kgp protease inhibitor.

Authors:  M A Curtis; J Aduse Opoku; M Rangarajan; A Gallagher; J A C Sterne; C R Reid; H E A Evans; B Samuelsson
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  Gingipains: Critical Factors in the Development of Aspiration Pneumonia Caused by Porphyromonas gingivalis.

Authors:  Małgorzata Benedyk; Piotr Mateusz Mydel; Nicolas Delaleu; Karolina Płaza; Katarzyna Gawron; Aleksandra Milewska; Katarzyna Maresz; Joanna Koziel; Krzysztof Pyrc; Jan Potempa
Journal:  J Innate Immun       Date:  2015-11-28       Impact factor: 7.349

9.  Cleavage of human transferrin by Porphyromonas gingivalis gingipains promotes growth and formation of hydroxyl radicals.

Authors:  Véronique Goulet; Bradley Britigan; Koji Nakayama; Daniel Grenier
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  In vitro models of tissue penetration and destruction by Porphyromonas gingivalis.

Authors:  Elisoa Andrian; Daniel Grenier; Mahmoud Rouabhia
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.